Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
This rapid risk assessment addresses the public health risk associated with a previously unrecognised international spread of near pandrug-resistant strains of S. epidermidis as a cause of infection in several countries including EU Member States.
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
The goal of this systematic review is to update the 2011 ECDC risk assessment. Evidence from this review will be used to develop guidance on this topic.
This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.
The Latvian Centre for Disease Prevention and Control – on behalf of the Ministry of Health of the Republic of Latvia – requested the European Centre for Disease Prevention and Control to evaluate the current national reference laboratory (NRL) system.
An organ perfusion solution known as Viaspan® has been identified as being potentially contaminated with Bacillus cereus. Viaspan®, which is used to preserve organs prior to transplantation, is distributed to a number of countries around the world.According to ECDC's risk assessment, the likelihood of contamination and risk of infection in recipients or potential recipients of organ transplants preserved in Viaspan® solution produced after July 2011 appears to be low, based on the negative results of microbiological cultures in solution samples and the absence of reported patient cases to date. Nevertheless, vigilance is recommended to mitigate the risk.